blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4043041

EP4043041 - CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  23.06.2023
Database last updated on 11.09.2024
FormerThe application has been published
Status updated on  15.07.2022
Most recent event   Tooltip23.06.2023Application deemed to be withdrawnpublished on 26.07.2023  [2023/30]
Applicant(s)For all designated states
Technische Universität München
Arcisstr. 21
80333 München / DE
[2022/33]
Inventor(s)01 / Konrad, Matthias
80939 München / DE
02 / Schottelius, Margret
1005 Lausanne / CH
03 / Wester, Hans-Jürgen
85301 Schweitenkirchen / DE
 [2022/33]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2022/33]
Application number, filing date21157225.015.02.2021
[2022/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4043041
Date:17.08.2022
Language:EN
[2022/33]
Search report(s)(Supplementary) European search report - dispatched on:EP09.08.2021
ClassificationIPC:A61K51/08, A61P35/00, A61K101/02, A61K103/00, A61K103/30
[2022/33]
CPC:
A61K51/08 (EP); A61K51/088 (EP); A61P35/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/33]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:CXCR4-LIGANDEN ZUR DIAGNOSTISCHEN UND THERAPEUTISCHEN VERWENDUNG UND IHRE VORLÄUFER[2022/33]
English:CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF[2022/33]
French:CXCR4-LIGANDS POUR USAGE DIAGNOSTIQUE ET THÉRAPEUTIQUE ET LEURS PRÉCURSEURS[2022/33]
Examination procedure18.02.2023Application deemed to be withdrawn, date of legal effect  [2023/30]
13.03.2023Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2023/30]
Fees paidPenalty fee
Additional fee for renewal fee
28.02.202303   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[AD]WO2011131735  (UNIV MUENCHEN TECH [DE], et al) [AD] 1-15* the whole document *;
 [A]CN102626522B  (HAN YANJIANG) [A] 1-15 * the whole document *;
 [AD]WO2015185162  (TECH UNIVERSITÄT MÜNCHEN [DE]) [AD] 1-15 * the whole document *;
 [XDYI]WO2020053255  (UNIV MUENCHEN TECH [DE]) [XD] 1-5,7-15 * claims 1, 9, 10, 12,13, formula (I)-(III); page 13, line 9 to page 15, line 2; page 59, lines 2ff * [Y] 6 [I] 6;
 [A]  - Theresa Osl, "Development of cyclic pentapeptide ligands for chemokine receptor targeting", (20170101), URL: http://mediatum.ub.tum.de/doc/1342124/1342124.pdf, XP055626839 [A] 1-15 * the whole document *
 [A]  - Osl ET AL, "Elektronische Prüfungsarbeiten", (20180315), URL: http://mediatum.ub.tum.de/print/1342124.pdf, (20190927), XP055626918 [A] 1-15 * the whole document *
 [Y]  - OSL THERESA ET AL, "A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency", THERANOSTICS, AU, vol. 10, no. 18, doi:10.7150/thno.45537, ISSN 1838-7640, (20200101), pages 8264 - 8280, URL: https://www.thno.org/v10p8264.pdf, XP055827484 [Y] 6 * figure 1; paragraph bridging the columns of page 8271 *

DOI:   http://dx.doi.org/10.7150/thno.45537
by applicantWO2007096662
 WO2008150689
 WO2009027706
 WO2011131735
 WO2012118124
 US8410059
 US8765683
 WO2015185162
 WO2020053255
    - ZLOTNIKAYOSHIE O, "Chemokines", Immunity, (20000000), vol. 12, pages 121 - 127
    - DOMANSKA UMKRUIZINGA RCNAGENGAST WB et al., "A review on CXCR4/CXCL12 axis in oncology: No place to hide", Eur J Cancer, (20130000), vol. 49, doi:10.1016/j.ejca.2012.05.005, pages 219 - 230, XP002724533

DOI:   http://dx.doi.org/10.1016/j.ejca.2012.05.005
    - FENG YBRODER CCKENNEDY PEBERGER EA, "HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor", Science, (19960000), vol. 272, doi:10.1126/science.272.5263.872, pages 872 - 877, XP002027999

DOI:   http://dx.doi.org/10.1126/science.272.5263.872
    - NAGASAWA THIROTA STACHIBANA K et al., "Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1", Nature, (19960000), vol. 382, doi:10.1038/382635a0, pages 635 - 638, XP002115695

DOI:   http://dx.doi.org/10.1038/382635a0
    - "Chemokines and Their Receptors in Lymphocyte Traffic and HIV Infection", LOETSCHER PMOSER BBAGGIOLINI M, Advances in Immunology, Elsevier, (19990000), vol. 74, pages 127 - 180
    - AIUTI AWEBB IJBLEUL CSPRINGER TGUTIERREZ-RAMOS JC, "The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood", J Exp Med, (19970000), vol. 185, doi:10.1084/jem.185.1.111, pages 111 - 120, XP000866066

DOI:   http://dx.doi.org/10.1084/jem.185.1.111
    - BURGER JABURGER MKIPPS TJ, "Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells", Blood, (19990000), vol. 94, pages 3658 - 3667, XP003009551
    - MULLER AHOMEY BSOTO H et al., "Involvement of chemokine receptors in breast cancer metastasis", Nature, (20010000), vol. 410, doi:10.1038/35065016, pages 50 - 56, XP002292390

DOI:   http://dx.doi.org/10.1038/35065016
    - BURGER JAKIPPS TJ, "CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment", Blood, (20060000), vol. 107, doi:10.1182/blood-2005-08-3182, pages 1761 - 1767, XP002465982

DOI:   http://dx.doi.org/10.1182/blood-2005-08-3182
    - CHATTERJEE SBEHNAM AZAD BNIMMAGADDA S, "The intricate role of CXCR4 in cancer", Adv Cancer Res, (20140000), vol. 124, doi:10.1016/B978-0-12-411638-2.00002-1, pages 31 - 82, XP055369748

DOI:   http://dx.doi.org/10.1016/B978-0-12-411638-2.00002-1
    - GUO FWANG YLIU JMOK SCXUE FZHANG W, "CXCL12/CXCR4: A symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks", Oncogene, (20160000), vol. 35, doi:10.1038/onc.2015.139, pages 816 - 826, XP055380594

DOI:   http://dx.doi.org/10.1038/onc.2015.139
    - ORIMO AGUPTA PBSGROI DC et al., "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion", Cell, (20050000), vol. 121, doi:10.1016/j.cell.2005.02.034, pages 335 - 348, XP009138583

DOI:   http://dx.doi.org/10.1016/j.cell.2005.02.034
    - TAMAMURA HXU YHATTORI T et al., "A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140", Biochem Biophys Res Commun, (19980000), vol. 253, doi:10.1006/bbrc.1998.9871, pages 877 - 882, XP002169961

DOI:   http://dx.doi.org/10.1006/bbrc.1998.9871
    - TAMAMURA HKURODA MMASUDA M et al., "A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]- polyphemusin II), determined by nuclear magnetic resonance", Biochimica et Biophysics Acta (BBA) - Protein Structure and Molecular Enzymology, (19930000), vol. 1163, doi:10.1016/0167-4838(93)90183-R, pages 209 - 216, XP023469735

DOI:   http://dx.doi.org/10.1016/0167-4838(93)90183-R
    - TAMAMURA HWAKI MIMAI M et al., "Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr 5, 12 , Lys 7 ]-Polyphemusin II), with the maintenance of anti-HIV activity and solution structure 1", Bioorganic & Medicinal Chemistry, (19980000), vol. 6, pages 473 - 479
    - TAMAMURA HHIRAMATSU KMIZUMOTO M et al., "Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists", Org Biomol Chem, (20030000), vol. 1, doi:10.1039/B306613B, pages 3663 - 3669, XP008125665

DOI:   http://dx.doi.org/10.1039/B306613B
    - GEORGE GPCSTEVENS EABERG O et al., "Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging", Bioorganic & Medicinal Chemistry, (20140000), vol. 22, doi:10.1016/j.bmc.2013.12.012, pages 796 - 803, XP028668769

DOI:   http://dx.doi.org/10.1016/j.bmc.2013.12.012
    - JACOBSON OWEISS IDKIESEWETTER DOFARBER JMCHEN X, "PET of tumor CXCR4 expression with 4-18F-T140", J Nucl Med, (20100000), vol. 51, doi:10.2967/jnumed.110.079418, pages 1796 - 1804, XP002716818

DOI:   http://dx.doi.org/10.2967/jnumed.110.079418
    - YAN XNIU GWANG Z et al., "AI18FNOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression", Mol Imaging Biol, (20160000), vol. 18, doi:10.1007/s11307-015-0872-2, pages 135 - 142, XP035936449

DOI:   http://dx.doi.org/10.1007/s11307-015-0872-2
    - PENG S-BZHANG XPAUL D et al., "Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies", PLoS ONE, (20160000), vol. 11, doi:10.1371/journal.pone.0150585, page e0150585, XP055368885

DOI:   http://dx.doi.org/10.1371/journal.pone.0150585
    - PORTELLA LVITALE RLUCA S DE et al., "Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases", PLoS ONE, (20130000), vol. 8, page e74548
    - TSUTSUMI HTANAKA TOHASHI N et al., "Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents", Biopolymers, (20070000), vol. 88, doi:10.1002/BIP.20653, pages 279 - 289, XP002629052

DOI:   http://dx.doi.org/10.1002/BIP.20653
    - TAMAMURA HARAKI TUEDA S et al., "Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds", J Med Chem, (20050000), vol. 48, doi:10.1021/jm050009h, pages 3280 - 3289, XP002460443

DOI:   http://dx.doi.org/10.1021/jm050009h
    - TAMAMURA HESAKA AOGAWA T et al., "Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds", Org Biomol Chem, (20050000), vol. 3, doi:10.1039/b513145f, pages 4392 - 4394, XP009082932

DOI:   http://dx.doi.org/10.1039/b513145f
    - TANAKA TNOMURA WNARUMI T et al., "Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: The exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids", Org Biomol Chem, (20090000), vol. 7, pages 3805 - 3809
    - NARUMI THAYASHI RTOMITA K et al., "Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres", Org Biomol Chem, (20100000), vol. 8, doi:10.1039/B917236J, pages 616 - 621, XP002668500

DOI:   http://dx.doi.org/10.1039/B917236J
    - UEDA SOISHI SWANG Z-X et al., "Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: Disclosing the importance of side-chain and backbone functionalities", J Med Chem, (20070000), vol. 50, doi:10.1021/jm0607350, pages 192 - 198, XP009107403

DOI:   http://dx.doi.org/10.1021/jm0607350
    - WU BCHIEN EYTMOL CD et al., "Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists", Science, (20100000), vol. 330, doi:10.1126/science.1194396, pages 1066 - 1071, XP055036210

DOI:   http://dx.doi.org/10.1126/science.1194396
    - DEMMER ODIJKGRAAF ISCHUMACHER U et al., "Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4", J Med Chem, (20110000), vol. 54, doi:10.1021/jm2009716, pages 7648 - 7662, XP055052231

DOI:   http://dx.doi.org/10.1021/jm2009716
    - TANAKA TNOMURA WNARUMI TMASUDA ATAMAMURA H, "Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells", J Am Chem Soc, (20100000), vol. 132, doi:10.1021/ja107447w, pages 15899 - 15901, XP055524518

DOI:   http://dx.doi.org/10.1021/ja107447w
    - ÁVILA-SÁNCHEZ MFERRO-FLORES GJIMENEZ-MANCILLA N et al., "Synthesis and preclinical evaluation of the 99mTc-/177Lu-CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting", J Radioanal Nucl Chem, (20200000), vol. 324, doi:10.1007/s10967-020-07043-6, pages 21 - 32, XP037078523

DOI:   http://dx.doi.org/10.1007/s10967-020-07043-6
    - VALLEJO-ARMENTA PSANTOS-CUEVAS CSOTO-ANDONAEGUI J et al., "99mTc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans", Contrast Media Mol Imaging, (20200000), page 2525037
    - DEMMER ODIJKGRAAF ISCHOTTELIUS MWESTER H-JKESSLER H, "Introduction of functional groups into peptides via N-alkylation", Org Lett, (20080000), vol. 10, pages 2015 - 2018
    - DEMMER OGOURNI ESCHUMACHER UKESSLER HWESTER H-J, "PET imaging of CXCR4 receptors in cancer by a new optimized ligand", ChemMedChem, (20110000), vol. 6, doi:10.1002/cmdc.201100320, pages 1789 - 1791, XP055544161

DOI:   http://dx.doi.org/10.1002/cmdc.201100320
    - GOURNI EDEMMER OSCHOTTELIUS M et al., "PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent", J Nucl Med, (20110000), vol. 52, pages 1803 - 1810
    - POSCHENRIEDER ASCHOTTELIUS MSCHWAIGER MKESSLER HWESTER H-J, "The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity", EJNMMI Res, (20160000), vol. 6, doi:10.1186/s13550-016-0193-8, page 36, XP055388769

DOI:   http://dx.doi.org/10.1186/s13550-016-0193-8
    - HERRMANN KSCHOTTELIUS MLAPA C et al., "First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease", J Nucl Med, (20160000), vol. 57, doi:10.2967/jnumed.115.167361, pages 248 - 251, XP055544057

DOI:   http://dx.doi.org/10.2967/jnumed.115.167361
    - OSL TSCHMIDT ASCHWAIGER MSCHOTTELIUS MWESTER H-J, "A new class of PentixaFor-and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency", Theranostics, (20200000), vol. 10, pages 8264 - 8280
    - SCHOTTELIUS MKONRAD MOSL TPOSCHENRIEDER AWESTER H-J, "An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides", Tetrahedron Letters, (20150000), vol. 56, doi:10.1016/j.tetlet.2015.10.032, pages 6602 - 6605, XP029321717

DOI:   http://dx.doi.org/10.1016/j.tetlet.2015.10.032
    - DEMMER OFRANK AOHAGN F et al., "Erhohte CXCR4-Affinitat und Anti-HIV-Aktivitat eines Peptoids durch Konformationsfixierung", Angew. Chem., (20120000), vol. 124, pages 8234 - 8237
    - CHATTERJEE JGILON CHOFFMAN AKESSLER H, "N-methylation of peptides: A new perspective in medicinal chemistry", Acc Chem Res, (20080000), vol. 41, doi:10.1021/ar8000603, pages 1331 - 1342, XP055164292

DOI:   http://dx.doi.org/10.1021/ar8000603
    - WEINEISEN MSIMECEK JSCHOTTELIUS MSCHWAIGER MWESTER H-J, "Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer", EJNMMI Res, (20140000), vol. 4, doi:10.1186/s13550-014-0063-1, page 63, XP055753565

DOI:   http://dx.doi.org/10.1186/s13550-014-0063-1
    - LOVKOVA LWANGLER BSCHIRRMACHER E et al., "para-Functionalized aryl-di-tert-butylfluorosilanes as potential labeling synthons for (18)F radiopharmaceuticals", Chemistry, (20090000), vol. 15, doi:10.1002/chem.200802266, pages 2140 - 2147, XP055071336

DOI:   http://dx.doi.org/10.1002/chem.200802266
    - KOSTIKOV APLOVKOVA LCHIN J et al., "N-(4-(di-tert-butyl[18F]fluorosilyl)benzyl)-2-hydroxy-N,N-dimethylethylammonium bromide ([18F]SiFAN+Br-): A novel lead compound for the development of hydrophilic SiFA-based prosthetic groups for 18F-labeling", Journal of Fluorine Chemistry, (20110000), vol. 132, pages 27 - 34, XP027576116
    - ABRAMS MJJUWEID MTENKATE CI et al., "Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats", J Nucl Med, (19900000), vol. 31, pages 2022 - 2028, XP000164904
    - JOYARD YBISCHOFF LLEVACHER VPAPAMICAEL CVERA PBOHN P, "Synthesis and Stability Evaluation of New HYNIC Derivatives as Ligands for Technetium-99m", LOC, (20140000), vol. 11, pages 208 - 214
    - SCHOTTELIUS MSCHWAIGER MWESTER H-J, "Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA", Tetrahedron Letters, (20030000), vol. 44, doi:10.1016/S0040-4039(03)00221-1, pages 2393 - 2396, XP004411178

DOI:   http://dx.doi.org/10.1016/S0040-4039(03)00221-1
    - SCHOTTELIUS MOSL TPOSCHENRIEDER A et al., "177Lupentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent", Theranostics, (20170000), vol. 7, doi:10.7150/thno.19119, pages 2350 - 2362, XP055544221

DOI:   http://dx.doi.org/10.7150/thno.19119
    - ROBU SSCHOTTELIUS MEIBER M et al., "Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer", J Nucl Med, (20170000), vol. 58, doi:10.2967/jnumed.116.178939, pages 235 - 242, XP055774139

DOI:   http://dx.doi.org/10.2967/jnumed.116.178939
    - KUZMANOVSKA SVASKOVA OZDRAVESKA KOCOVSKA M, "In-house'' preparation of 99mTc-EDDA/HYNIC-TOC, a specific targeting agent for somatostatin receptor scintigraphy", Maced. Pharm. Bull., (20110000), vol. 57, pages 65 - 70
    - WANGLER CNIEDERMOSER SCHIN J et al., "One-step (18)F-labeling of peptides for positron emission tomography imaging using the SiFA methodology", Nat Protoc, (20120000), vol. 7, doi:10.1038/nprot.2012.109, pages 1946 - 1955, XP037298690

DOI:   http://dx.doi.org/10.1038/nprot.2012.109
    - OTHMAN MFBMITRY NRLEWINGTON VJBLOWER PJTERRY SYA, "Re-assessing gallium-67 as a therapeutic radionuclide", Nucl Med Biol, (20170000), vol. 46, doi:10.1016/j.nucmedbio.2016.10.008, pages 12 - 18, XP029900122

DOI:   http://dx.doi.org/10.1016/j.nucmedbio.2016.10.008
    - YAMAZAKI KKANAOKA M, "Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds", J Pharm Sci, (20040000), vol. 93, pages 1480 - 1494
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.